Acadia Healthcare Company, Inc. (DE:7RA)
NASDAQ:7RA
7RA Stock Chart & Stats
€22.40
-€0.80(-1.80%)
At close: 4:00 PM EST
€22.40
-€0.80(-1.80%)
Day’s Range― - ―
52-Week Range€9.65 - €24.20
Previous CloseN/A
Volume0.00
Average Volume (3M)68.00
Market Cap
€2.21B
Enterprise Value€4.67B
Total Cash (Recent Filing)€158.47M
Total Debt (Recent Filing)€2.67B
Price to Earnings (P/E)―
Beta-0.07
Next Earnings
Aug 04, 2026EPS Estimate
0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.24
Shares Outstanding91,967,026
10 Day Avg. Volume200
30 Day Avg. Volume68
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.66
Price to Sales (P/S)0.39
P/FCF Ratio-2.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€25.28Price Target Upside12.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)1.29
Revenue Forecast (FY)€2.94B
Bulls Say, Bears Say
Bulls Say
Stable Same‑facility Revenue GrowthConsistent same‑facility revenue growth, driven by higher revenue per patient day and modest patient day gains, signals durable underlying demand for behavioral health services. This supports steady organic top‑line expansion and improves predictability of revenue as new beds and ramps compound growth.
Operational Execution And Margin DisciplineManagement delivered cost efficiencies, reduced corporate headcount and beat EBITDA guidance, then raised full‑year profitability targets. These actions reflect structural improvements to operating leverage and expense control that can sustainably lift margins as volumes normalize and start‑up losses decline.
Meaningful Organic Capacity Expansion And JVsA multi‑year pipeline of bed additions and joint ventures expands capacity and referral relationships, enabling revenue diversification and higher long‑term utilization. Once facilities ramp, incremental margins and scale benefits can materially accrete to EBITDA and support sustained growth.
Bears Say
Elevated Leverage And Reduced FlexibilityLeverage has increased materially versus prior years, leaving the company more sensitive to interest rates, payer timing and payout variability. Elevated net leverage restricts strategic optionality, raises refinancing risk, and can constrain investments if cash generation underperforms guidance.
Sharp Deterioration In Profitability And Earnings QualityA large swing to deep losses and negative margins represents a structural weakening in earnings quality. Persistent profitability shortfalls erode returns on equity, limit internally generated capital for growth, and increase reliance on external funding during cyclical or regulatory stress.
Significant Legal Overhang And Contingent LiabilityA sizable jury verdict creates material financial uncertainty and potential cash outflow, with appeal outcomes unclear. Legal exposure can divert management focus, raise insurance and settlement costs, and impair relationships with payors or referral sources if reputational effects persist.
Acadia Healthcare News
7RA FAQ
What was Acadia Healthcare Company, Inc.’s price range in the past 12 months?
Acadia Healthcare Company, Inc. lowest stock price was €9.65 and its highest was €24.20 in the past 12 months.
What is Acadia Healthcare Company, Inc.’s market cap?
Acadia Healthcare Company, Inc.’s market cap is €2.21B.
When is Acadia Healthcare Company, Inc.’s upcoming earnings report date?
Acadia Healthcare Company, Inc.’s upcoming earnings report date is Aug 04, 2026 which is in 38 days.
How were Acadia Healthcare Company, Inc.’s earnings last quarter?
Acadia Healthcare Company, Inc. released its earnings results on Apr 29, 2026. The company reported €0.319 earnings per share for the quarter, beating the consensus estimate of €0.228 by €0.09.
Is Acadia Healthcare Company, Inc. overvalued?
According to Wall Street analysts Acadia Healthcare Company, Inc.’s price is currently Undervalued.
Does Acadia Healthcare Company, Inc. pay dividends?
Acadia Healthcare Company, Inc. does not currently pay dividends.
What is Acadia Healthcare Company, Inc.’s EPS estimate?
Acadia Healthcare Company, Inc.’s EPS estimate is 0.31.
How many shares outstanding does Acadia Healthcare Company, Inc. have?
Acadia Healthcare Company, Inc. has 91,967,026 shares outstanding.
What happened to Acadia Healthcare Company, Inc.’s price movement after its last earnings report?
Acadia Healthcare Company, Inc. reported an EPS of €0.319 in its last earnings report, beating expectations of €0.228. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Acadia Healthcare Company, Inc.?
Currently, no hedge funds are holding shares in DE:7RA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acadia Healthcare Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€25.28 (12.85% Upside)
€25.28 (12.85% Upside)
Blogger Sentiment
Bullish
DE:7RA Sentiment 70%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.31%
12-Months-Change
Fundamentals
Return on Equity
-43.82%
Trailing 12-Months
Asset Growth
-9.78%
Trailing 12-Months
Company Description
Acadia Healthcare Company, Inc.
Acadia Healthcare Company, Inc. specializes in delivering a comprehensive range of behavioral health services, with its operations spanning the United States and Puerto Rico. Patients receive care in diverse environments, including acute inpatient psychiatric hospitals, specialized treatment facilities, long-term residential centers, and outpatient clinics. As of March 31, 2022, the company managed an extensive network consisting of 238 behavioral healthcare facilities, collectively providing approximately 10,600 beds. Established in 2005, Acadia Healthcare is headquartered in Franklin, Tennessee.
7RA Company Deck
7RA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a constructive operational and financial start to 2026: revenue and adjusted EBITDA grew, results beat guidance, management raised full-year profitability targets, and execution initiatives (leadership changes, cost efficiencies, bed additions, JVs, technology) are showing early benefits. Offsetting these positives are persistent challenges in specialty (notably Pennsylvania), slower CTC performance due to weather, elevated bad debts/denials, temporary higher leverage in Q2 from timing of supplemental payments, and ongoing start-up/closure headwinds. Overall, progress on operations and margins appears to outweigh the headwinds, though some risks (payer behavior and supplemental approvals) remain.View all DE:7RA earnings summaries7RA Stock 12 Month Forecast
Average Price Target
€25.28
▲(12.85% Upside)
Technical Analysis
Brookdale Senior Living
―
National Healthcare
―
Select Medical
―
Surgery Partners
―
Lifestance Health Group
―
Options Prices
Currently, No data available
---